CNSB004 (leconotide) causes antihyperalgesia without side effects when given intravenously: A comparison with ziconotide in a rat model of diabetic neuropathic pain

Pain Medicine

Volumn 11, Issue 2, 2010, Pages 262-273

  Kolosov, Anton ^a   Goodchild, Colin S ^b   Cooke, Ian ^b  

^a MONASH UNIVERSITY   (Australia)

^b CNSBio Ltd Pty Ltd   (Australia)

Author keywords

Antinociception; Conopeptide; Diabetic neuropathy; Drug synergy; Flupirtine; Leconotide; Ziconotide

Indexed keywords

CNSB 004; FLUPIRTINE; LECONOTIDE; OMEGA CONOTOXIN; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; PLACEBO; STREPTOZOCIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHANNEL GATING; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG POTENTIATION; HEAT; HYPERALGESIA; HYPOTENSION; MALE; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; NON INVASIVE MEASUREMENT; NONHUMAN; OPEN FIELD BEHAVIOR; PAIN THRESHOLD; RAT; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 75249106626     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00741.x     Document Type: Article

References (28)

1. Norton RS, Pallaghy PK, Baell JB. Polypeptide omega-conotoxin GVIA as a basis for new analgesic and neuroprotective agents. Drug Dev Res 1999, 46(3-4):206-18.
2. Williams JA, Day M, Heavner JE. Ziconotide: An update and review. Expert Opin Pharmacother 2008, 9(9):1575-83.
3. Wallace MS, Kosek PS, Staats P. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008, 9(3):271-81.
4. Klotz U. Ziconotide-A novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain-A short review. Int J Clin Pharmacol Ther 2006, 44(10):478-83.
5. McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: First demonstration of N-channel function in humans. J Cardiovasc Pharmacol 1997, 30(3):400-3.
6. Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain 2000, 85(1-2):291-6.
7. Pruneau D, Angus JA. Omega-conotoxin GVIA is a potent inhibitor of sympathetic neurogenic responses in rat small mesenteric arteries. Br J Pharmacol 1990, 100(1):180-4.
8. Pruneau D, Angus JA. Omega-conotoxin GVIA, the N-type calcium channel inhibitor, is sympatholytic but not vagolytic: Consequences for hemodynamics and autonomic reflexes in conscious rabbits. J Cardiovasc Pharmacol 1990, 16(4):675-80.
9. Lewis RJ, Nielsen KJ, Craik DJ. Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 2000, 275(45):35335-44.
10. Scott DA, Wright CE, Angus JA. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 2002, 451(3):279-86.
11. Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002, 96(1-2):119-27.
12. Cousins MJ, Leal GCC. A phase I clinical trial of AM336, a novel N-type calcium channel blocker. 10th World Congress on Pain, San Diego, California, poster 615-P249. 2002, August
13. Sharp D. Novel pain relief via marine snails. Lancet 2005, 366(9484):439-40.
14. Wright CE, Robertson AD, Whorlow SL, Angus JA. Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. Br J Pharmacol 2000, 131(7):1325-36.
15. Bowersox SS, Singh T, Luther RR. Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal cerebral ischemia in rats. Brain Res 1997, 747(2):343-7.
16. Wang YX, Bowersox SS. Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels. CNS Drug Rev 2000, 6(1):1-20.
17. Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. J Neural Transm 1999, 106(9-10):857-67.
18. Zimmerman M. Ethical guidelines for investigation of experimental pain on conscious animals. Pain 1983, 16:109-10.
19. Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: Behavioural evidence for a model of chronic pain. Pain 1993, 53:81-8.
20. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994, 57(2):153-60.
21. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88.
22. Randall LO, Selitto JJ. A method for measurement of analgesic activity of inflamed tissue. Arch Int Pharmacodyn Ther 1957, 111:409-19.
23. Hawkes AL, Angus JA, Wright CE. Omega-conotoxin GVIA and prazosin, but not felodipine, cause postural hypotension in rabbits. Clin Exp Pharmacol Physiol 1995, 22(10):711-16.
24. Nielsen KJ, Schroeder T, Lewis R. Structure-activity relationships of omega-conotoxins at N-type voltage-sensitive calcium channels. J Mol Recognit 2000, 13(2):55-70.
25. Lewis RJ. Conotoxins: Molecular and therapeutic targets. Prog Mol Subcell Biol 2009, 46:45-65.
26. Lundy PM, Frew R. Evidence of omega-conotoxin GV1A-sensitive Ca2+ channels in mammalian peripheral nerve terminals. Eur J Pharmacol 1988, 156(3):325-30.
27. Yang WP, Levesque PC, Little WA. Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. J Biol Chem 1998, 273(31):19419-23.
28. Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 1980, 283(5748):673-6.